Travere Therapeutics Moves Forward with sNDA Submission for FILSPARI
Travere Therapeutics, Inc. (Nasdaq: TVTX), based in San Diego, has completed a critical Type C meeting with the U.S. Food and Drug Administration (FDA). This meeting has set the stage for the company to submit a supplemental New Drug Application (sNDA) for FILSPARI (sparsentan), targeting the treatment of focal segmental glomerulosclerosis (FSGS). The projected timeline for this submission is around the end of the first quarter of 2025.
The Potential of FILSPARI for FSGS Patients
FSGS is a rare yet devastating kidney disorder that contributes significantly to kidney failure, impacting over 40,000 individuals in the U.S. This condition results in the progressive scarring of kidney tissues, often leading to severe complications.
Dr. Eric Dube, president and CEO of Travere Therapeutics, expressed optimism regarding the company's progress, stating, "We are pleased with the outcome of our Type C meeting and to be moving forward with an sNDA submission to add a potential FSGS indication for FILSPARI in the U.S. Treatment options for FSGS are desperately needed as there are currently no approved medicines indicated for this devastating, progressive and complex rare kidney disorder." The company plans to utilize data from the Phase 3 DUPLEX and Phase 2 DUET studies, which are some of the most extensive interventional studies conducted for FSGS.
Understanding FSGS and Its Challenges
FSGS leads to proteinuria, a condition characterized by excess protein in the urine due to the breakdown of the kidney's filtration system. This excess protein is toxic to the kidneys and can worsen the overall condition. Symptoms also include swelling, low blood albumin levels, abnormal lipid profiles, and hypertension. Regrettably, there is currently no approved pharmacological treatment for this rare disease.
Insights from the DUPLEX and DUET Studies
The DUPLEX study is heralded as the largest interventional study in FSGS, demonstrating significant efficacy in reducing proteinuria and providing crucial insights for the upcoming sNDA submission. Although it achieved its primary endpoint for partial remission of proteinuria, it did not meet the primary efficacy eGFR slope endpoint over the duration of the study. The two-year results, however, indicated meaningful benefits for patients, with notable rates of proteinuria reduction and lower rates of end-stage kidney disease.
The DUET study further corroborated the effectiveness of sparsentan, showing a greater than two-fold reduction in protein levels compared to irbesartan. Both studies have been pivotal in shaping the evidence base for FILSPARI’s potential approval for FSGS.
Conference Call and Company Engagement
Travere Therapeutics will host a conference call and webcast to discuss these developments, reaching out to investors and stakeholders to ensure transparency. Details regarding participation will be made available on the investor relations page of the company’s website.
PARASOL Workgroup Findings
The Type C meeting followed findings from the PARASOL workgroup, which emphasized the significance of proteinuria reduction over a sustained period as a critical marker for improved kidney outcomes. These insights are expected to support the sNDA submission significantly.
About Travere Therapeutics
Travere Therapeutics is committed to addressing the urgent need for treatment options for rare diseases. The company’s ethos centers around understanding the complex needs of patients facing these conditions. They are dedicated to developing and delivering innovative therapies designed to effect positive change in the lives of those affected by rare diseases.
Future Aspirations with FILSPARI
As Travere Therapeutics forges ahead with its sNDA submission, the hope is to position FILSPARI as a groundbreaking treatment option for FSGS, potentially transforming care for the thousands suffering from this rare kidney disorder. With ongoing studies and regulatory engagement, the company aspires to provide a beacon of hope for patients and families impacted by FSGS.
Frequently Asked Questions
What is FILSPARI and what is its significance?
FILSPARI (sparsentan) is a medication aimed at slowing the decline of kidney function in patients with FSGS, which is a rare kidney disorder with no currently approved treatment.
Why is the FDA meeting important for Travere Therapeutics?
The Type C meeting with the FDA provided critical feedback and alignment on the sNDA submission for FILSPARI, ensuring the company is on track to seek approval for an important new indication.
What are the DUPLEX and DUET studies?
The DUPLEX and DUET studies are pivotal clinical trials that assessed the efficacy of FILSPARI in treating FSGS, providing crucial data for the upcoming sNDA submission.
What is the timeline for the sNDA submission?
The submission is expected to be filed by the end of the first quarter of 2025, following the successful completion of the FDA meeting.
How does Travere Therapeutics engage with the patient community?
The company actively collaborates with the rare disease community to understand patient needs, aiming to deliver effective therapies that significantly improve patient outcomes.
